These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 14991069)

  • 1. Concordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesions.
    Quaglino E; Rolla S; Iezzi M; Spadaro M; Musiani P; De Giovanni C; Lollini PL; Lanzardo S; Forni G; Sanges R; Crispi S; De Luca P; Calogero R; Cavallo F
    J Clin Invest; 2004 Mar; 113(5):709-17. PubMed ID: 14991069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.
    Lo Iacono M; Cavallo F; Quaglino E; Rolla S; Iezzi M; Pupa SM; De Giovanni C; Lollini PL; Musiani P; Forni G; Calogero RA
    Int J Immunopathol Pharmacol; 2005; 18(2):351-63. PubMed ID: 15888257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice.
    Nanni P; Nicoletti G; De Giovanni C; Landuzzi L; Di Carlo E; Cavallo F; Pupa SM; Rossi I; Colombo MP; Ricci C; Astolfi A; Musiani P; Forni G; Lollini PL
    J Exp Med; 2001 Nov; 194(9):1195-205. PubMed ID: 11696586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine.
    De Giovanni C; Nicoletti G; Landuzzi L; Astolfi A; Croci S; Comes A; Ferrini S; Meazza R; Iezzi M; Di Carlo E; Musiani P; Cavallo F; Nanni P; Lollini PL
    Cancer Res; 2004 Jun; 64(11):4001-9. PubMed ID: 15173014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.
    Rovero S; Amici A; Di Carlo E; Bei R; Nanni P; Quaglino E; Porcedda P; Boggio K; Smorlesi A; Lollini PL; Landuzzi L; Colombo MP; Giovarelli M; Musiani P; Forni G
    J Immunol; 2000 Nov; 165(9):5133-42. PubMed ID: 11046045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAG-3 enables DNA vaccination to persistently prevent mammary carcinogenesis in HER-2/neu transgenic BALB/c mice.
    Cappello P; Triebel F; Iezzi M; Caorsi C; Quaglino E; Lollini PL; Amici A; Di Carlo E; Musiani P; Giovarelli M; Forni G
    Cancer Res; 2003 May; 63(10):2518-25. PubMed ID: 12750275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice.
    Di Carlo E; Rovero S; Boggio K; Quaglino E; Amici A; Smorlesi A; Forni G; Musiani P
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):830s-837s. PubMed ID: 11300480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination.
    Pupa SM; Iezzi M; Di Carlo E; Invernizzi A; Cavallo F; Meazza R; Comes A; Ferrini S; Musiani P; Ménard S
    Cancer Res; 2005 Feb; 65(3):1071-8. PubMed ID: 15705909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario.
    Astolfi A; Rolla S; Nanni P; Quaglino E; De Giovanni C; Iezzi M; Musiani P; Forni G; Lollini PL; Cavallo F; Calogero RA
    Cancer Immunol Immunother; 2005 Jun; 54(6):599-610. PubMed ID: 15690207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent.
    Nanni P; Landuzzi L; Nicoletti G; De Giovanni C; Rossi I; Croci S; Astolfi A; Iezzi M; Di Carlo E; Musiani P; Forni G; Lollini PL
    J Immunol; 2004 Aug; 173(4):2288-96. PubMed ID: 15294941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice.
    Quaglino E; Iezzi M; Mastini C; Amici A; Pericle F; Di Carlo E; Pupa SM; De Giovanni C; Spadaro M; Curcio C; Lollini PL; Musiani P; Forni G; Cavallo F
    Cancer Res; 2004 Apr; 64(8):2858-64. PubMed ID: 15087404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early role of CD4+ Th1 cells and antibodies in HER-2 adenovirus vaccine protection against autochthonous mammary carcinomas.
    Park JM; Terabe M; Sakai Y; Munasinghe J; Forni G; Morris JC; Berzofsky JA
    J Immunol; 2005 Apr; 174(7):4228-36. PubMed ID: 15778385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intramammary application of non-methylated-CpG oligodeoxynucleotides (CpG) inhibits both local and systemic mammary carcinogenesis in female BALB/c Her-2/neu transgenic mice.
    Mastini C; Becker PD; Iezzi M; Curcio C; Musiani P; Forni G; Cavallo F; Guzmán CA
    Curr Cancer Drug Targets; 2008 May; 8(3):230-42. PubMed ID: 18473736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP110-HER2/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2/neu transgenic mice.
    Manjili MH; Wang XY; Chen X; Martin T; Repasky EA; Henderson R; Subjeck JR
    J Immunol; 2003 Oct; 171(8):4054-61. PubMed ID: 14530326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.
    Astolfi A; Landuzzi L; Nicoletti G; De Giovanni C; Croci S; Palladini A; Ferrini S; Iezzi M; Musiani P; Cavallo F; Forni G; Nanni P; Lollini PL
    Am J Pathol; 2005 Apr; 166(4):1205-16. PubMed ID: 15793299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice.
    Wang X; Wang JP; Rao XM; Price JE; Zhou HS; Lachman LB
    Breast Cancer Res; 2005; 7(5):R580-8. PubMed ID: 16168101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice.
    Masuelli L; Marzocchella L; Focaccetti C; Lista F; Nardi A; Scardino A; Mattei M; Turriziani M; Modesti M; Forni G; Schlom J; Modesti A; Bei R
    Cancer Immunol Immunother; 2010 Aug; 59(8):1247-58. PubMed ID: 20364378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus vaccination against neu oncogene exerts long-term protection from tumorigenesis in BALB/neuT transgenic mice.
    Gallo P; Dharmapuri S; Nuzzo M; Maldini D; Cipriani B; Forni G; Monaci P
    Int J Cancer; 2007 Feb; 120(3):574-84. PubMed ID: 17096348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system.
    Croci S; Recktenwald CV; Lichtenfels R; Nicoletti G; Dressler SP; De Giovanni C; Astolfi A; Palladini A; Shin-ya K; Landuzzi L; Nanni P; Lollini PL; Seliger B
    Proteomics; 2010 Nov; 10(21):3835-53. PubMed ID: 20957756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice.
    Jacob J; Radkevich O; Forni G; Zielinski J; Shim D; Jones RF; Wei WZ
    Cell Immunol; 2006 Apr; 240(2):96-106. PubMed ID: 16930573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.